In our study, we found that deletion of IL-18 in the PBC mouse model did not change disease progression, while deletion of IL-21 restrained the AMA level but not liver inflammation, and deletion of IFN-γ restrained both AMA level and liver inflammation. This evidence concerns the gene IL18 and primary biliary cholangitis.